David Blaine Ridley

Journal article Review of Economics and Statistics · December 1, 2020 Featured Publication Medicare reimburses health care providers for the drugs they administer. Since 2005, it has reimbursed based on the past price of the drug. Reimbursement on past prices could motivate manufacturers to set higher launch prices because providers become less ... Full text Cite

Strategic interaction among governments in the provision of a global public good

Journal article Journal of Public Economics · December 1, 2017 Featured Publication How do governments respond to other governments when providing a global public good? Using data from 2007 to 2014 on medical research funding for infectious and parasitic diseases, we examine how governments and foundations in 41 countries respond to fundi ... Full text Open Access Cite

A Voucher System To Speed Review Could Promote A New Generation Of Insecticides To Fight Vector-Borne Diseases.

Journal article Health affairs (Project Hope) · August 2017 Featured Publication Many in the scientific community are concerned about the potential increase in prevalence of insect-borne diseases such as Chagas disease, Chikungunya, dengue fever, malaria, and Zika in the United States and around the world. Beyond vaccines and drugs to ... Full text Cite

The role of government reimbursement in drug shortages

Journal article American Economic Journal Economic Policy · May 1, 2017 Featured Publication Beginning in the mid- 2000s, the incidence of drug shortages rose, especially for generic injectable drugs such as anesthetics and chemotherapy treatments. We examine whether reimbursement changes contributed to the shortages, focusing on a reduction in Me ... Full text Open Access Cite

Regulation of price increases

Journal article International Journal of Industrial Organization · January 1, 2017 Featured Publication U.S. federal and state governments rarely regulate healthcare price levels, but do regulate price changes for pharmaceuticals, hospitals, and health insurance. Previous research showed that limiting price increases can raise launch prices and reduce both p ... Full text Cite

The Commercial Market For Priority Review Vouchers.

Journal article Health affairs (Project Hope) · May 2016 Featured Publication In 2007 the US Congress created the priority review voucher program to encourage the development of drugs for neglected diseases. Under the program, the developer of a drug that treats a neglected disease receives both a faster review of the drug by the Fo ... Full text Cite

Efficacy of the Priority Review Voucher Program.

Journal article JAMA · April 2016 Featured Publication Full text Cite

Market watch: Forecasting market share in the US pharmaceutical market.

Journal article Nature reviews. Drug discovery · September 2015 Featured Publication Full text Cite

Forecasting Market Share in the US Pharmaceutical Market

Journal article Nature Reviews Drug Discovery. 2015. · July 31, 2015 Featured Publication Cite

Pharmaceutical followers

Journal article International Journal of Industrial Organization · November 15, 2013 Featured Publication We estimate a model of drug demand and supply that incorporates insurance, advertising, and competition between branded and generic drugs within and across therapeutic classes. We use data on antiulcer drugs from 1991 to 2010. Our simulations show that gen ... Full text Cite

Innovation incentives under transferable fast-track regulatory review

Journal article Journal of Industrial Economics · September 1, 2013 Featured Publication Under a 2007 U.S. law, the developer of a treatment for a neglected disease is rewarded with a fast-track voucher that can be sold to another developer. Similar fast-track vouchers are being offered by other agencies. We model how the existence of transfer ... Full text Cite

Payments, promotion, and the purple pill

Journal article Health Economics (United Kingdom) · 2013 Featured Publication Understanding competition in the US drug market requires knowing how sensitive demand is to prices. The relevant prices for insured consumers are copayments. There are many studies of copayment elasticity in the health literature, but they are of limited a ... Full text Cite

Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases.

Journal article Lancet · September 11, 2010 Featured Publication Every year 1 billion people worldwide are affected by traditionally neglected diseases, such as malaria, tuberculosis, leishmaniasis, and lymphatic filariasis, which impose tremendous public health burdens. Governments, foundations, and drug manufacturers ... Full text Link to item Cite

Developing drugs for developing countries.

Journal article Health Aff (Millwood) · 2006 Featured Publication Infectious and parasitic diseases create enormous health burdens, but because most of the people suffering from these diseases are poor, little is invested in developing treatments. We propose that developers of treatments for neglected diseases receive a ... Full text Open Access Link to item Cite